Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (59,146)	$ (8,249)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	489	299
Stock-based compensation	3,329	29
Non-cash research and development expenses	20,000
Non-cash lease expense	448	289
Non-cash loss from equity method investment in joint venture	50
Change in fair value of derivative liability	5,821
Changes in operating assets and liabilities:
Prepaid and other current assets	(836)	(84)
Accounts payable	610	117
Accrued expenses and other current liabilities	3,164	960
Operating lease liabilities	(455)	(278)
Derivative liability	3,369
Net cash used in operating activities	(23,157)	(6,917)
Cash flows from investing activities
Purchase of property and equipment	(540)	(1,483)
Investment in joint venture	(50)
Net cash used in investing activities	(590)	(1,483)
Cash flows from financing activities
Proceeds from issuance of Series B Convertible Preferred Stock, net of issuance costs	151,581
Deferred offering costs	(2,451)
Proceeds from the issuance of common stock		3
Proceeds from the exercise of stock options	14	31
Net cash provided by financing activities	149,144	34
Net (decrease) increase in cash, cash equivalents, and restricted cash	125,397	(8,366)
Cash, cash equivalents and restricted cash at beginning of period	8,189	19,721
Cash, cash equivalents and restricted cash at end of period	133,586	11,355
Supplemental schedule of noncash operating and financing activities:
Deferred offering costs in accounts payable and accrued expenses	1,050
Operating lease right-of-use asset obtained in exchange for new operating lease liabilities		1,186
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	133,477	11,246
Restricted cash	109	109
Cash, cash equivalents and restricted cash at end of period	$ 133,586	$ 11,355